CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, which is being held virtually from June 8-11, 2021.
Anish Suri, president and chief scientific officer of Cue Biopharma, will discuss preclinical data on CUE-401, the Company’s most recent autoimmune drug product candidate. CUE-401, part of the CUE-400 series designed for differentiation and expansion of induced regulatory T cells (iTregs), is a bispecific molecule engineered to deliver the two signals, transforming growth factor beta (TGF-β) and interleukin 2 (IL-2), required to induce iTregs in vivo.
Session Title: CUE-401: A Novel IL-2/TGF-beta Fusion Protein for the Induction of CD4+ FOXP3+ Regulatory T cells
Presenter: Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma
Session: Late Breaking Abstracts (Part II)
Date and Time: Thursday, June 10, 2021 from 3:45 p.m. – 4:00 p.m. PDT
The recorded presentation and poster will be available in the Investor & Media section of the Company’s website under Scientific Publications and Presentations, following the presentation at FOCIS 2021 annual meeting.
Presentation data highlights include:
- In vivo data show that CUE-401 can effectively induce FOXP3-expressing iTregs from T cells obtained from healthy donors as well as patients suffering from rheumatoid arthritis and inflammatory bowel diseases.
- CUE-401 induced iTregs suppressed effector T cell responses.
- A single dose of CUE-401 was shown effective at inducing Tregs in mice with active and ongoing autoimmunity.
Dr. Suri commented, “We are very excited to share these promising preclinical data demonstrating CUE-401 has the ability to induce and expand regulatory T cells in vitro and in vivo. We believe this is an innovative and potentially effective means of suppressing chronic inflammatory diseases and may provide a more meaningful and lasting benefit to patients suffering from numerous autoimmune diseases, graft versus host disease (GVHD) and even transplant rejection.”
About FOCIS Annual Meeting
The Federation of Clinical Immunology Societies is a key forum where opinion leaders come together to chart the path to the next major breakthrough in disease therapy. Through FOCIS, researchers and clinicians share knowledge across traditional disease borders, and identify commonalities between treatments and therapies that are life-changing for those impacted by immune-mediated diseases. The FOCIS Annual Meeting educates clinicians, researchers and trainees in the broad discipline of clinical immunology. FOCIS is the world’s leader in immunology education and in training future generations of clinical immunologists. Initially established as a cross-disciplinary meeting, FOCIS held its first Annual Meeting in 2001. After two successful consecutive meetings, FOCIS was incorporated as a 501(c)3 organization in 2003. Today, FOCIS has 58 Member Societies, representing roughly 65,000 clinician scientists.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body to transform the treatment of cancer, infectious disease and autoimmune disease. The company’s proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform, is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the company’s estimate of the period in which it expects to have cash to fund its operations; the company’s belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the company’s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s limited operating history, limited cash and a history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the company’s trials; negative or inconclusive results from the company’s clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future; operations and clinical the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
George B. Zavoico, Ph.D.
VP, Investor Relations & Corporate Development
Cue Biopharma, Inc.
Darren Opland, Ph.D.